Cargando…

Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre‐existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuznetsova, Anna, Lebedev, Aleksey, Gromov, Konstantin, Kazennova, Elena, Zazzi, Maurizio, Incardona, Francesca, Sönnerborg, Anders, Bobkova, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813671/ https://www.ncbi.nlm.nih.gov/pubmed/35140966 http://dx.doi.org/10.1002/ccr3.5373

Ejemplares similares

Human Immunodeficiency Virus-1 Diversity in the Moscow Region, Russia: Phylodynamics of the Most Common Subtypes
por: Lebedev, Aleksey, et al.
Publicado: (2019)

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy
por: Svärd, Jenny, et al.
Publicado: (2017)

Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology
por: Pereira, Mariana, et al.
Publicado: (2023)

Prevalence and spatiotemporal dynamics of HIV-1 Circulating Recombinant Form 03_AB (CRF03_AB) in the Former Soviet Union countries
por: Lebedev, Aleksey, et al.
Publicado: (2020)

Correction: Prevalence and spatiotemporal dynamics of HIV-1 Circulating Recombinant Form 03_AB (CRF03_AB) in the Former Soviet Union countries
por: Lebedev, Aleksey, et al.
Publicado: (2021)

Molecular Epidemiology of HIV-1 in Eastern Europe and Russia
por: van de Klundert, Maarten A. A., et al.
Publicado: (2022)

1590. Resistance to Etravirine, Doravine and Rilpivirine in People Living with HIV Experiencing Virologic Failure to a First-line Antiretroviral Regimen Based on a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in a Latin American Country.
por: Mingrone, Verónica, et al.
Publicado: (2023)

Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Petchkum, Porkaew, et al.
Publicado: (2019)

Identifying HIV-1 Transmission Clusters in Uzbekistan through Analysis of Molecular Surveillance Data
por: Lebedev, Aleksey, et al.
Publicado: (2022)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Human Immunodeficiency Virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells
por: Davis, Adam J, et al.
Publicado: (2008)

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012)

Safety of rilpivirine plus nucleoside reverse-transcriptase inhibitors in HIV-infected Taiwanese with a higher prevalence of hepatitis virus infection
por: Wu, Pei-Ying, et al.
Publicado: (2014)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Mutations in the Reverse Transcriptase and Protease Genes of Human Immunodeficiency Virus-1 from Antiretroviral Naïve and Treated Pediatric Patients
por: Bure, Dinesh, et al.
Publicado: (2015)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature
por: Achhra, Amit C, et al.
Publicado: (2013)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
por: Suzuki, Takefumi, et al.
Publicado: (2017)

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2014)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

A25 Analysis of non-structural genes subtype A1 HIV-1 circulating in Russia
por: Gromov, K, et al.
Publicado: (2018)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Features of Tat Protein in HIV-1 Sub-Subtype A6 Variants Circulating in the Moscow Region, Russia
por: Kuznetsova, Anna, et al.
Publicado: (2023)

Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)
por: Rossetti, Barbara, et al.
Publicado: (2023)

Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine
por: Singh, Abhimanyu K., et al.
Publicado: (2022)

MiR-138-5p Suppresses Cell Growth and Migration in Melanoma by Targeting Telomerase Reverse Transcriptase
por: Tarazón, Estefanía, et al.
Publicado: (2021)

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans
por: Collins, Sean E., et al.
Publicado: (2016)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
por: Murray, Miranda, et al.
Publicado: (2020)

Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia
por: Konstantopoulos, Christina, et al.
Publicado: (2015)

Comparison of Two Antiretroviral Therapy Regimens in Human Immunodeficiency Virus (HIV−) Infected Pregnant Women
por: Tate, Danielle, et al.
Publicado: (2017)

Biochemical mechanism of clinical resistance to rilpivirine
por: Singh, Kamalendra, et al.
Publicado: (2012)

The development of an effective synthetic route of rilpivirine
por: Zhang, Tao, et al.
Publicado: (2021)

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
por: Singh, Kamal, et al.
Publicado: (2019)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
por: Pironti, A, et al.
Publicado: (2010)

Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
por: Weisser, Hendrik, et al.
Publicado: (2010)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eccsi7fmme6e6t80rg8brlho1k